Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

A Real-world Evidence-based Management of HIV by Differential Duration HAART Treatment and its Association with Incidence of Oral Lesions

Author(s): Wen Shu, Fei Du, Jin-Song Bai, Ling-Yun Yin, Kai-Wen Duan and Cheng-Wen Li*

Volume 20, Issue 1, 2022

Published on: 21 January, 2022

Page: [91 - 99] Pages: 9

DOI: 10.2174/1570162X20666211227154558

open access plus

Abstract

Background: The efficacy of highly active antiretroviral therapy (HAART) can be estimated by the immunological response and the incidence of opportunistic infections.

Objective: This study aimed at evaluating the effectiveness of different durations of HAART in terms of immunological response markers (CD4 count and CD4/CD8 ratio) along with disease progression markers (incidence of oral lesions) in Chinese patients with HIV.

Methods: This single-center, retrospective, and real-world study included patients with HIV, grouped into a treatment group and treatment-naïve group, of which the former was further divided into 6, 12, and 18 months based on the treatment duration. The CD4 and CD8 cell counts were analyzed by the FACSCalibur flow cytometry. Kruskal-Wallis test was applied to determine the outcome of different duration of HAART. Oral examination was carried out according to the WHO type IV examination.

Results: In 246 patients with HIV, CD4 counts increased significantly post-HAART compared to pre-HAART in all three treatment groups (P<.001), while CD8 count decreased significantly (P<.05) in all three treated groups. A significant association of HAART with the CD4/CD8 ratio was observed (P<.001). A significant increase in CD4 count was observed between 12-months and 18-months treatment groups (P<.05). The occurrence of oral lesions reduced significantly in the treatment group.

Conclusion: We observed a better response to the HAART regimen with 18-months of duration than 12-months and 6-months therapies and reduction in oral lesions.

Keywords: Highly active antiretroviral therapy, duration of HAART therapy, HIV, real-world study, CD4 and CD8 count, immunological response.

« Previous
Graphical Abstract
[1]
Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med 2009; 265(1): 78-96.
[http://dx.doi.org/10.1111/j.1365-2796.2008.02043.x] [PMID: 19093962]
[2]
Korencak M, Byrne M, Richter E, et al. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight 2019; 4(12): 126675.
[http://dx.doi.org/10.1172/jci.insight.126675] [PMID: 31217351]
[3]
Khaitan A, Unutmaz D. Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011; 8(1): 4-11.
[http://dx.doi.org/10.1007/s11904-010-0066-0] [PMID: 21188556]
[4]
Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JAM. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol 2013; 4: 298.
[http://dx.doi.org/10.3389/fimmu.2013.00298] [PMID: 24133492]
[5]
WHO. The Global Health Observatory (GHO). Explore a world of health data. Available from: https://www.who.int/data/gho
[6]
Cui Y, Shi CX, Wu Z. Epidemiology of HIV/AIDS in China: Recent trends. Glob Health J 2017; 1(1): 26-32.
[http://dx.doi.org/10.1016/S2414-6447(19)30057-0]
[7]
Bodhade AS, Ganvir SM, Hazarey VK. Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci 2011; 53(2): 203-11.
[http://dx.doi.org/10.2334/josnusd.53.203] [PMID: 21712625]
[8]
Patton LL. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90(2): 182-8.
[http://dx.doi.org/10.1067/moe.2000.108799] [PMID: 10936837]
[9]
Pinheiro A, Marcenes W, Zakrzewska JM, Robinson PG. Dental and oral lesions in HIV infected patients: A study in Brazil. Int Dent J 2004; 54(3): 131-7.
[http://dx.doi.org/10.1111/j.1875-595x.2004.tb00268.x] [PMID: 15218892]
[10]
Jindwani K. A study of oral lesions among H.I.V. positives in a tertiary care hospital. Biomed Res 2013; (24): 40-2.
[11]
Shu W, Li C, Du F, Bai J, Duan K. A real-world, cross sectional study of oral lesions and their association with CD4 cell counts and HIV viral load in Yunnan, China. Medicine (Baltimore) 2020; 99(40): e22416.
[http://dx.doi.org/10.1097/MD.0000000000022416] [PMID: 33019418]
[12]
Adurogbangba MI, Aderinokun GA, Odaibo GN, Olaleye OD, Lawoyin TO. Oro-facial lesions and CD4 counts associated with HIV/AIDS in an adult population in Oyo State, Nigeria. Oral Dis 2004; 10(6): 319-26.
[http://dx.doi.org/10.1111/j.1601-0825.2004.01036.x] [PMID: 15533205]
[13]
Collins DR, Gaiha GD, Walker BD. CD8+ T cells in HIV control, cure and prevention. Nat Rev Immunol 2020; 20(8): 471-82.
[http://dx.doi.org/10.1038/s41577-020-0274-9] [PMID: 32051540]
[14]
Zhang C, Hu W, Jin JH, et al. The role of CD8 T cells in controlling HIV beyond the antigen-specific face. HIV Med 2020; 21(11): 692-700.
[http://dx.doi.org/10.1111/hiv.13021] [PMID: 33369032]
[15]
Lu W, Chen S, Lai C, et al. Suppression of HIV replication by CD8(+) regulatory T-Cells in elite controllers. Front Immunol 2016; 7: 134.
[http://dx.doi.org/10.3389/fimmu.2016.00134] [PMID: 27148256]
[16]
Benito JM, López M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev 2004; 6(2): 79-88.
[PMID: 15332430]
[17]
Mayer KH, Venkatesh KK. Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health 2010; 100(10): 1867-76.
[http://dx.doi.org/10.2105/AJPH.2009.184796] [PMID: 20724682]
[18]
Kasamba I, Baisley K, Mayanja BN, Maher D, Grosskurth H. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999-2009. Trop Med Int Health 2012; 17(8): e66-73.
[http://dx.doi.org/10.1111/j.1365-3156.2012.02841.x] [PMID: 22943381]
[19]
Zhao Y, Wu Z, McGoogan JM, et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in china: A nationwide, retrospective cohort study. Clin Infect Dis 2018; 66(5): 727-34.
[http://dx.doi.org/10.1093/cid/cix878] [PMID: 29069362]
[20]
McBride J. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog 2017; 13(11): e1006624.
[http://dx.doi.org/10.1371/journal.ppat.1006624] [PMID: 29095912]
[21]
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
[http://dx.doi.org/10.1056/NEJMoa1105243] [PMID: 21767103]
[22]
Umadevi KMR, Ranganathan K, Pavithra S, et al. Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India. J Oral Pathol Med 2007; 36(3): 136-41.
[http://dx.doi.org/10.1111/j.1600-0714.2006.00505.x] [PMID: 17305634]
[23]
Margolis DM. Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses 2011; 27(4): 347-53.
[http://dx.doi.org/10.1089/AID.2011.0017] [PMID: 21314240]
[24]
Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun 2018; 9(1): 4811.
[http://dx.doi.org/10.1038/s41467-018-06843-5] [PMID: 30446650]
[25]
Permanyer M, Ballana E, Ruiz A, et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J Virol 2012; 86(16): 8773-80.
[http://dx.doi.org/10.1128/JVI.01044-12] [PMID: 22696642]
[26]
HIV and AIDS in China. Available from: https://www.avert.org/professionals/hiv-around-world/asia-pacific/china (Accessed on Oct 3, 2019)
[27]
Time between diagnosis and initiation of antiretroviral therapy among people infected with HIV/AIDS from 2004 to 2016 in China: A retrospective database study - The Lancet Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32637-0/fulltext#articleInformation Accessed Oct 3, 2019
[28]
Li T, Dai Y, Kuang J, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 2008; 3(12): e3918.
[http://dx.doi.org/10.1371/journal.pone.0003918] [PMID: 19081791]
[29]
Luo L, Li TS. Overview of antiretroviral treatment in China: Advancement and challenges. Chin Med J (Engl) 2011; 124(3): 440-4.
[http://dx.doi.org/10.3760/cma.j.issn.0366-6999.2011.03.022] [PMID: 21362348]
[30]
Li L, Sun G, Liang S, et al. Different distribution of HIV-1 subtype and drug resistance were found among treatment naïve individuals in Henan, Guangxi, and Yunnan province of China. PLoS One 2013; 8(10): e75777.
[http://dx.doi.org/10.1371/journal.pone.0075777] [PMID: 24098398]
[31]
Pennings PS. HIV drug resistance: Problems and perspectives. Infect Dis Rep 2013; 5(Suppl. 1): e5.
[http://dx.doi.org/10.4081/idr.2013.s1.e5] [PMID: 24470969]
[32]
Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS 2000; 14(15): 2257-63.
[http://dx.doi.org/10.1097/00002030-200010200-00006] [PMID: 11089613]
[33]
Annison L, Dompreh A, Adu-Sarkodie Y. The immunological response of HIV-positive patients initiating HAART at the komfo anokye teaching hospital, Kumasi, Ghana. Ghana Med J 2013; 47(4): 164-70.
[PMID: 24669021]
[34]
Candiani TMS, Pinto J, Cardoso CAA, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 2007; 23(Suppl. 3): S414-23.
[http://dx.doi.org/10.1590/s0102-311x2007001500009] [PMID: 17992347]
[35]
Low A, Gavriilidis G, Larke N, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: A systematic review and meta-analysis. Clin Infect Dis 2016; 62(12): 1595-603.
[http://dx.doi.org/10.1093/cid/ciw125] [PMID: 26951573]
[36]
Lok JJ, Bosch RJ, Benson CA, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010; 24(12): 1867-76.
[http://dx.doi.org/10.1097/QAD.0b013e32833adbcf] [PMID: 20467286]
[37]
Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. PLoS One 2015; 10(3): e0122583.
[http://dx.doi.org/10.1371/journal.pone.0122583] [PMID: 25816222]
[38]
Kagan JM, Sanchez AM, Landay A, Denny TN. A brief chronicle of CD4 as a biomarker for HIV/AIDS: A tribute to the memory of John L. Fahey. For Immunopathol Dis Therap 2015; 6(1-2): 55-64.
[http://dx.doi.org/10.1615/ForumImmunDisTher.2016014169] [PMID: 27182452]
[39]
Sempa JB, Rossouw TM, Lesaffre E, Nieuwoudt M. Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models. PLoS One 2019; 14(11): e0224723.
[http://dx.doi.org/10.1371/journal.pone.0224723] [PMID: 31721805]
[40]
Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy J-P. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18: 20052.
[http://dx.doi.org/10.7448/IAS.18.1.20052] [PMID: 26130226]
[41]
Lee SS, Wong NS, Wong BCK, Wong KH, Chan KCW. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study. BMJ Open 2017; 7(9): e016886.
[http://dx.doi.org/10.1136/bmjopen-2017-016886] [PMID: 28918411]
[42]
Shyam R, Singh A, Singh DK, et al. A Prospective study to compare the effect of different HAART regimens on cd4 counts of HIV patients with tuberculosis. Int J Pharm Sci Res 8(5): 2218-22.
[43]
Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV care. Curr Opin HIV AIDS 2017; 12(2): 123-8.
[http://dx.doi.org/10.1097/COH.0000000000000348] [PMID: 28059957]
[44]
Li C-X, Li Y-Y, He L-P, et al. The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China. BMC Immunol 2019; 20(1): 31.
[http://dx.doi.org/10.1186/s12865-019-0311-2] [PMID: 31455209]
[45]
Yen Y-F, Chen M, Jen I-A, et al. Short- and long-term risks of highly active antiretroviral treatment with incident opportunistic infections among people living with HIV/AIDS. Sci Rep 2019; 9(1): 3476.
[http://dx.doi.org/10.1038/s41598-019-39665-6] [PMID: 30837537]
[46]
Nittayananta W, Talungchit S, Jaruratanasirikul S, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39(5): 397-406.
[http://dx.doi.org/10.1111/j.1600-0714.2009.00875.x] [PMID: 20202089]
[47]
Maloth S, Shrinivas TR, Krishna Pramod B, Nagarathna PJ. Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study. J Family Med Prim Care 2020; 9(9): 4821-5.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_881_20] [PMID: 33209807]
[48]
Ottria L, Lauritano D, Oberti L, et al. Prevalence of HIV-related oral manifestations and their association with HAART and CD4+ T cell count: A review. J Biol Regul Homeost Agents 2018; 32(2 Suppl. 1): 51-9.
[PMID: 29460518]
[49]
Greenspan D, Gange SJ, Phelan JA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 2004; 83(2): 145-50.
[http://dx.doi.org/10.1177/154405910408300212] [PMID: 14742653]
[50]
Nicolatou-Galitis O, Velegraki A, Paikos S, et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004; 10(3): 145-50.
[http://dx.doi.org/10.1046/j.1601-0825.2003.00994.x] [PMID: 15089923]
[51]
Butt FMA, Vaghela VP, Chindia ML. Correlation of CD4 counts and CD4/CD8 ratio with HIV-infection associated oral manifestations. East Afr Med J 2007; 84(8): 383-8.
[http://dx.doi.org/10.4314/eamj.v84i7.9546] [PMID: 17970007]
[52]
Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000; 14(12): 627-35.
[http://dx.doi.org/10.1089/10872910050206540] [PMID: 11119429]
[53]
Gaurav S, Keerthilatha PM, Archna N. Prevalence of oral manifestations and their association with cd4/cd8 ratio and HIV Viral load in South India. Int J Dent 2011; 2011: 964278.
[http://dx.doi.org/10.1155/2011/964278] [PMID: 22046186]
[54]
Classification and Diagnostic Criteria for Oral Lesions in HIV Infection. EC-clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus. J Oral Pathol Med 1993; 22(7): 289-91.
[PMID: 8229864]
[55]
Aškinytė D, Matulionytė R, Rimkevičius A. Oral manifestations of HIV disease: A review. Stomatologija 2015; 17(1): 21-8.
[PMID: 26183854]
[56]
Sun J-J, Lu H-Z. Highlights of the third edition of Chinese guidelines for AIDS diagnosis and treatment(2015). Zhejiang Xue Xue Bao Yi Xue Ban 2015; 44(6): 597-602.
[PMID: 26822040]
[57]
Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197(5): 707-13.
[http://dx.doi.org/10.1086/527416] [PMID: 18266607]
[58]
Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013; 254(1): 54-64.
[http://dx.doi.org/10.1111/imr.12066] [PMID: 23772614]
[59]
Eggleton JS, Nagalli S. Highly active antiretroviral therapy (HAART). StatPearls. Treasure Island (FL): StatPearls Publishing 2020.
[PMID: 32119420]
[60]
Hoffman J. Role of the CD4 count in HIV management. HIV Ther 2010; 4(1): 27-39.
[http://dx.doi.org/10.2217/hiv.09.58]
[61]
Krantz E M, Hullsiek K H, Okulicz J F, et al. Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. J Acquir Immune Defic Syndr 1999 2011; 57(5): 396-403.
[http://dx.doi.org/10.1097/QAI.0b013e318221c62a] [PMID: 21602694]
[62]
Margolick JB, Gange SJ, Detels R, O’Gorman MRG, Rinaldo CR Jr, Lai S. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42(5): 620-6.
[http://dx.doi.org/10.1097/01.qai.0000223028.55080.9d] [PMID: 16868499]
[63]
Stranford SA, Ong JC, Martinez-Marino B, et al. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci USA 2001; 98(2): 597-602.
[http://dx.doi.org/10.1073/pnas.98.2.597] [PMID: 11136234]
[64]
Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190(10): 1860-8.
[http://dx.doi.org/10.1086/425075] [PMID: 15499544]
[65]
Sainz T, Serrano-Villar S, Díaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 2013; 27(9): 1513-6.
[http://dx.doi.org/10.1097/QAD.0b013e32835faa72] [PMID: 23435292]
[66]
Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015; 2(3): e98-e106.
[http://dx.doi.org/10.1016/S2352-3018(15)00006-5] [PMID: 26424550]
[67]
Saracino A, Bruno G, Scudeller L, et al. Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio. AIDS Res Hum Retroviruses 2014; 30(12): 1178-84.
[http://dx.doi.org/10.1089/aid.2014.0080] [PMID: 25360575]
[68]
Gojak R, Hadžiosmanović V, Baljić R, Zečević L, Ćorić J, Mijailović Ž. CD4/CD8 ratio as a predictor for the occurrence of metabolic syndrome in HIV / AIDS patients during 6 months of cART therapy. J Med Biochem 2019; 38(4): 489-95.
[http://dx.doi.org/10.2478/jomb-2018-0049] [PMID: 31496914]
[69]
Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, et al. Oral clinical markers and viral load in a prospective cohort of Mexican HIV-infected patients. AIDS 2001; 15(14): 1910-1.
[http://dx.doi.org/10.1097/00002030-200109280-00032] [PMID: 11579265]
[70]
Rao KVSE, Chitturi RT, Kattappagari KK, Kantheti LPC, Poosarla C, Baddam VRR. Impact of highly active antiretroviral therapy on oral manifestations of patients with human immunodeficiency virus/acquired immuno deficiency syndrome in South India. Indian J Sex Transm Dis AIDS 2015; 36(1): 35-9.
[http://dx.doi.org/10.4103/0253-7184.156703] [PMID: 26392652]
[71]
Lamster IB, Begg MD, Mitchell-Lewis D, et al. Oral manifestations of HIV infection in homosexual men and intravenous drug users. Study design and relationship of epidemiologic, clinical, and immunologic parameters to oral lesions. Oral Surg Oral Med Oral Pathol 1994; 78(2): 163-74.
[http://dx.doi.org/10.1016/0030-4220(94)90140-6] [PMID: 7936584]
[72]
He L, Pan X, Dou Z, et al. The factors related to cd4+ t-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of haart: A retrospective study of the national HIV treatment sub-database of Zhejiang province, China, 2014. PLoS One 2016; 11(2): e0148915.
[http://dx.doi.org/10.1371/journal.pone.0148915] [PMID: 26900702]

© 2024 Bentham Science Publishers | Privacy Policy